ZyCoV-D is the first DNA plasmid vaccine in the world for human use, developed indigenously by the company against the Covid-19 virus
CDSCO to fast-track trials and approval for COVID19 vaccine
The company posted net profit of Rs.19.36 crores for the period ended June 30, 2020.
The company posted net profit of Rs.19.36 crores for the period ended June 30, 2020.
The first six batches are being shipped to the Gamaleya Center, Moscow for the quality approval
The first batch will be shipped to the Gamaleya Center for the quality control
Targeted production of the dual vector Sputnik V for the first 12 months is 50 million doses from the date of start of commercial production
Financial support is being provided as a grant from the Government of India
The current production capacity of indigenously developed Covaxin vaccine will be doubled by May-June 2021 and then increased nearly 6-7 fold by July-August 2021.
Indian government is expecting pharmaceutical industry to fetch incremental sales worth Rs. 294,000 crore and exports up to Rs. 196,000 crore by FY 2027-28
Subscribe To Our Newsletter & Stay Updated
